These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10141 related articles for article (PubMed ID: 1830477)
41. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. Parkkinen J; Rauvala H J Biol Chem; 1991 Sep; 266(25):16730-5. PubMed ID: 1909331 [TBL] [Abstract][Full Text] [Related]
42. Mechanism of the stimulatory effect of native fucoidan, highly sulfated fucoidan and heparin on plasminogen activation by tissue plasminogen activator: the role of chloride. Lang D; Williams T; Phillips A; Doctor VM Eur J Drug Metab Pharmacokinet; 2004; 29(4):269-75. PubMed ID: 15726889 [TBL] [Abstract][Full Text] [Related]
43. Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin. Stack MS; Pizzo SV J Biol Chem; 1993 Sep; 268(25):18924-8. PubMed ID: 8360182 [TBL] [Abstract][Full Text] [Related]
44. The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage. Petersen LC; Johannessen M; Foster D; Kumar A; Mulvihill E Biochim Biophys Acta; 1988 Feb; 952(3):245-54. PubMed ID: 2962643 [TBL] [Abstract][Full Text] [Related]
45. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Husain SS; Hasan AA; Budzynski AZ Blood; 1989 Aug; 74(3):999-1006. PubMed ID: 2502209 [TBL] [Abstract][Full Text] [Related]
46. Comparison of recombinant tissue-type plasminogen activator (rt-PA) expressed in mouse C127 cells and human vascular plasminogen activator (HV-PA). Hamaguchi M; Takahashi I; Takehara T; Takamatsu J; Saito H Biochim Biophys Acta; 1989 Nov; 1009(2):143-50. PubMed ID: 2508748 [TBL] [Abstract][Full Text] [Related]
47. Myelin basic protein stimulates plasminogen activation via tissue plasminogen activator following binding to independent l-lysine-containing domains. Gonzalez-Gronow M; Fiedler JL; Farias Gomez C; Wang F; Ray R; Ferrell PD; Pizzo SV Biochem Biophys Res Commun; 2017 Aug; 490(3):855-860. PubMed ID: 28648598 [TBL] [Abstract][Full Text] [Related]
48. The role of the lysyl binding site of tissue-type plasminogen activator in the interaction with a forming fibrin clot. Bakker AH; Weening-Verhoeff EJ; Verheijen JH J Biol Chem; 1995 May; 270(21):12355-60. PubMed ID: 7759476 [TBL] [Abstract][Full Text] [Related]
49. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. Kornberg A; Francis CW; Marder VJ Blood; 1992 Aug; 80(3):709-17. PubMed ID: 1386260 [TBL] [Abstract][Full Text] [Related]
50. Fractionation of heparin by chromatography on a tissue plasminogen activator-Sepharose column. Andrade-Gordon P; Strickland S Proc Natl Acad Sci U S A; 1990 Mar; 87(5):1865-9. PubMed ID: 2106684 [TBL] [Abstract][Full Text] [Related]
51. Formation and elimination of soluble fibrin and D-dimer in the bloodstream. Udovenko A; Makogonenko Y; Korolova D; Druzhyna N; Chernyshenko V; Komisarenko S Croat Med J; 2023 Dec; 64(6):421-429. PubMed ID: 38168523 [TBL] [Abstract][Full Text] [Related]
52. Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin. Torr-Brown SR; Nachowiak D; Fujii S; Sobel BE Coron Artery Dis; 1994 Jul; 5(7):625-31. PubMed ID: 7952425 [TBL] [Abstract][Full Text] [Related]
54. In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography. Vlakh EG; Platonova GA; Vlasov GP; Kasper C; Tappe A; Kretzmer G; Tennikova TB J Chromatogr A; 2003 Apr; 992(1-2):109-19. PubMed ID: 12735467 [TBL] [Abstract][Full Text] [Related]
55. Some properties of tissue-type plasminogen activator reconstituted onto phospholipid and/or glycolipid vesicles. Soeda S; Kakiki M; Shimeno H; Nagamatsu A Biochem Biophys Res Commun; 1987 Jul; 146(1):94-100. PubMed ID: 3111472 [TBL] [Abstract][Full Text] [Related]
56. Further characterization of the binding of plasminogen to heparin: evidence for the involvement of lysine residues. Soeda S; Ohki H; Shimeno H; Nagamatsu A Biochim Biophys Acta; 1989 Nov; 999(1):29-35. PubMed ID: 2572276 [TBL] [Abstract][Full Text] [Related]
57. Production and characterization of single-chain tissue-type plasminogen activator produced by an established cell line from human uterine muscle. Matsuo O; Fukao H; Izaki S; Matsuo C; Ueshima S Cell Struct Funct; 1989 Feb; 14(1):45-60. PubMed ID: 2497995 [TBL] [Abstract][Full Text] [Related]
58. The inhibition of TNK-t-PA by C1-inhibitor. Sulikowski T; Patston PA Blood Coagul Fibrinolysis; 2001 Jan; 12(1):75-7. PubMed ID: 11229830 [TBL] [Abstract][Full Text] [Related]
59. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Fleury V; Anglés-Cano E Biochemistry; 1991 Jul; 30(30):7630-8. PubMed ID: 1677272 [TBL] [Abstract][Full Text] [Related]
60. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Harpel PC; Chang VT; Borth W Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10193-7. PubMed ID: 1438209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]